ImmuPharma (LON:IMM) Trading 13.9% Higher - Here's What Happened

Key Points

• Shares of ImmuPharma plc rose 13.9% during trading, reaching a high of GBX 15.15 from a previous close of GBX 11.13.
• Approximately 50 million shares were traded, a significant increase of 548% from the average daily volume.
• ImmuPharma reported earnings of GBX (0.38) per share and has a negative return on equity of 131.41% with forecasts suggesting a loss of -339.00 for the current year.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) traded up 13.9% on Wednesday . The company traded as high as GBX 15.15 ($0.21) and last traded at GBX 12.67 ($0.17). 50,412,297 shares traded hands during trading, an increase of 548% from the average session volume of 7,783,485 shares. The stock had previously closed at GBX 11.13 ($0.15).

ImmuPharma Stock Up 28.8%

The firm has a market capitalization of £69.86 million, a price-to-earnings ratio of -1,570.67 and a beta of 1.53. The business has a 50-day moving average of GBX 3.12 and a two-hundred day moving average of GBX 2.92.

ImmuPharma (LON:IMM - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.